G1SK34 logo

GSK BOVESPA:G1SK34 Stock Report

Last Price

R$42.56

Market Cap

R$435.3b

7D

1.2%

1Y

16.8%

Updated

26 Mar, 2024

Data

Company Financials +

G1SK34 Stock Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

G1SK34 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health3/6
Dividends3/6

GSK plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GSK
Historical stock prices
Current Share PriceUK£42.56
52 Week HighUK£43.16
52 Week LowUK£32.88
Beta0.26
1 Month Change0.61%
3 Month Change19.02%
1 Year Change16.79%
3 Year Changen/a
5 Year Changen/a
Change since IPO28.70%

Recent News & Updates

Recent updates

Shareholder Returns

G1SK34BR PharmaceuticalsBR Market
7D1.2%0.8%0.03%
1Y16.8%-9.2%22.4%

Return vs Industry: G1SK34 exceeded the BR Pharmaceuticals industry which returned -9.2% over the past year.

Return vs Market: G1SK34 underperformed the BR Market which returned 22.4% over the past year.

Price Volatility

Is G1SK34's price volatile compared to industry and market?
G1SK34 volatility
G1SK34 Average Weekly Movement2.5%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.6%
10% most volatile stocks in BR Market8.0%
10% least volatile stocks in BR Market2.3%

Stable Share Price: G1SK34 has not had significant price volatility in the past 3 months.

Volatility Over Time: G1SK34's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
171570,212Emma Walmsleyhttps://www.gsk.com

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

GSK plc Fundamentals Summary

How do GSK's earnings and revenue compare to its market cap?
G1SK34 fundamental statistics
Market capR$435.29b
Earnings (TTM)R$30.98b
Revenue (TTM)R$190.66b

14.1x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
G1SK34 income statement (TTM)
RevenueUK£30.33b
Cost of RevenueUK£8.39b
Gross ProfitUK£21.94b
Other ExpensesUK£17.01b
EarningsUK£4.93b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 01, 2024

Earnings per share (EPS)1.21
Gross Margin72.34%
Net Profit Margin16.25%
Debt/Equity Ratio131.4%

How did G1SK34 perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

48%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.